Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA acting CIO to depart

Executive Summary

FDA Acting Chief Information Officer Fred Farmer is leaving to return to a career in the private sector, effective July 22. Farmer assumed the role of acting CIO following the departure of CIO Jim Rinaldi last year (1"The Pink Sheet" Aug. 1, 2005, In Brief). FDA Associate Commissioner for Management and CFO Kathleen Heuer will assume the role of acting CIO as the agency completes its search for a permanent replacement...

You may also be interested in...



FDA information technology

FDA Information Technology Program Director Fred Farmer will become acting chief information officer Aug. 1 until a permanent replacement is found for departing CIO Jim Rinaldi. Rinaldi has accepted the CIO position with NASA's Jet Propulsion Laboratory; he became FDA's CIO in December 2002 ( 1"The Pink Sheet" Jan. 13, 2003, In Brief)...

Who’s Hired? Hikma Recruits New US Generics President

A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.

Organon And Henlius Complete Phase III For Denosumab

Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS047357

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel